Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 7/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.34 |
| ▸ | AR | P10275 | 3/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5698253 | 0.76 | PTPN2 (0.31) | — | |
| SCHEMBL16742787 | 0.76 | PTPN2 (0.31) | — | |
| SCHEMBL12215859 | 0.72 | PIK3CD (0.41) | — | |
| SCHEMBL13620942 | 0.72 | — | — | |
| SCHEMBL5367283 | 0.72 | — | — | |
| SCHEMBL12917968 | 0.68 | — | — | |
| SCHEMBL4973329 | 0.68 | — | — | |
| SCHEMBL1021333 | 0.68 | — | — | |
| SCHEMBL13706019 | 0.68 | — | — | |
| SCHEMBL2065243 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222667-B1 | NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD (CH) | 2013-02-20 | — | — | EP | disclosed |
| US-8148410-B2 | Thiophene derivatives as agonists of S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-04-03 | — | — | US | disclosed |
| US-20100261702-A1 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-10-14 | — | — | US | disclosed |
| EP-2222667-A2 | NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009074950-A2 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261702-A1 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | S1PR1, S1PR3, S1PR5 | PGR 2464/4885NR3C1 111/4885NR3C2 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.